Department of Pharmacy, Ogaki Municipal Hospital, 4-86 Minaminokawa-cho, Ogaki-city, Gifu, 503-8502, Japan.
Laboratory of Pharmacy Practice and Social Science, Gifu Pharmaceutical University, Gifu, Japan.
Eur J Clin Microbiol Infect Dis. 2019 Mar;38(3):593-600. doi: 10.1007/s10096-018-03465-z. Epub 2019 Jan 24.
Prospective audit with intervention and feedback (PAF) and preauthorisation of antimicrobials are core strategies for antimicrobial stewardship (AS). PAF participants were expanded from patients using specific antibiotics to those using whole injectable antibiotics to evaluate clinical outcome. From January 2016 to December 2016, PAF was performed in patients using specific antibiotics (period 1) and from January 2017 to December 2017, PAF was performed in patients using whole injectable antibiotics (period 2). PAF was implemented for 5 days every week by pharmacists involved in infectious diseases chemotherapy. In total, 11,571 and 11,103 patients used antibiotic injections during periods 1 and 2, respectively. No significant difference in mortality within 30 days from the initial use of injection antibiotics was observed. The average duration of hospitalisation was significantly shorter during period 2 among patients using antibiotics; however, this was not significantly different from that of patients not receiving antibiotics. The average duration of therapy for intravenous antibiotics was significantly shorter during period 2 than during period 1. The ratio of methicillin-resistant Staphylococcus aureus (MRSA) to S. aureus was significantly low during period 2. The duration of intravenous antibiotic therapy for Escherichia coli bacteraemia during period 2 decreased significantly. De-escalation and appropriate antimicrobial treatment rates at specific doses during period 2 increased significantly. Expansion of patients eligible for PAF from patients using specific antibiotics to patients using whole injectable antibiotics shortened hospital stays, suppressed drug resistance, and promoted the appropriate use of antibiotics.
前瞻性审核干预和反馈(PAF)以及抗生素的预授权是抗菌药物管理(AS)的核心策略。PAF 参与者从使用特定抗生素的患者扩展到使用整个注射用抗生素的患者,以评估临床结果。从 2016 年 1 月至 2016 年 12 月,对使用特定抗生素的患者进行了 PAF(第 1 期),从 2017 年 1 月至 2017 年 12 月,对使用整个注射用抗生素的患者进行了 PAF(第 2 期)。由参与传染病化疗的药剂师每周进行 5 天的 PAF。在第 1 期和第 2 期,分别有 11571 名和 11103 名患者使用抗生素注射剂。从开始使用注射用抗生素后 30 天内的死亡率无显著差异。使用抗生素的患者在第 2 期的住院时间明显缩短;然而,与未使用抗生素的患者相比,这并没有显著差异。在第 2 期,静脉用抗生素的治疗时间明显缩短。第 2 期耐甲氧西林金黄色葡萄球菌(MRSA)与金黄色葡萄球菌的比例明显较低。第 2 期大肠埃希菌菌血症的静脉用抗生素治疗时间明显缩短。第 2 期特定剂量的降阶梯和适当抗菌治疗率显著增加。将 PAF 合格患者从使用特定抗生素的患者扩展到使用整个注射用抗生素的患者,缩短了住院时间,抑制了耐药性,并促进了抗生素的合理使用。